PRIMARY IGA NEPHROPATHY
Clinical trials for PRIMARY IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for PRIMARY IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control Recruiting nowThis Phase 3 trial tests whether mezagitamab, an injectable drug, can reduce protein in the urine and preserve kidney function in adults with IgA nephropathy, a condition where immune complexes damage the kidneys. About 347 participants will receive either mezagitamab or a placeb…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug aims to slow kidney failure in IgA nephropathy patients
Disease control Recruiting nowThis phase 3 trial tests sefaxersen, a drug that targets a part of the immune system, in 428 people with IgA nephropathy at high risk of kidney decline. Participants receive either sefaxersen or a placebo as a shot under the skin. The main goal is to see if the drug reduces prote…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill aims to tame kidney disease in Long-Term trial
Disease control Recruiting nowThis study tests a new tablet called HSK39297 for people with IgA nephropathy, a kidney disease that can lead to kidney failure. The trial includes 73 adults who have already taken the drug in a previous study. They will take the tablet once daily for an extended period, with a p…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug aims to slow kidney disease in IgA nephropathy patients
Disease control Recruiting nowThis Phase 2 trial tests an investigational drug called SHR-2173 in 84 adults with primary IgA nephropathy, a kidney disease. Participants receive either a high, medium, or low dose of SHR-2173 or a placebo for 48 weeks. The main goal is to see if the drug reduces protein in the …
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug YKST02 aims to tame kidney disease in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called YKST02 in 12 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The main goal is to see if the drug is safe and tolerable, and to check if it reduces protein in the urine, a sign of kidney damage. Particip…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC